Personalis (PSNL)
(Delayed Data from NSDQ)
$1.30 USD
-0.08 (-5.80%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
PSNL 1.30 -0.08(-5.80%)
Will PSNL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PSNL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PSNL
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
PSNL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) Upgraded to Buy: Here's What You Should Know
Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates
Other News for PSNL
Personalis to Announce First Quarter 2024 Financial Results
Cathie Wood's Ark Laps Up $3.3M Worth Of Tesla As Stock Falls For 3rd Straight Session, Sheds Shares Of This Sports Betting Company
Buy Rating Affirmed for Personalis, Inc. on Strong Growth Prospects and Innovative Cancer Assays
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference